Browsing Tag
systemic mastocytosis
3 posts
Cogent Biosciences posts Q3 2025 results with $430m cash and pivotal trial momentum
Find out how Cogent Biosciences is using its $430 million cash runway and regulatory momentum to drive late-stage trials and pipeline expansion in 2025.
Blueprint Medicines highlights long-term clinical and real-world data for Ayvakit at EHA and EAACI 2025
Blueprint Medicines presents strong long-term survival and safety data for Ayvakit in systemic mastocytosis at EHA and EAACI 2025. Explore the clinical and market impact.
Hoth Therapeutics advances HT-KIT: Preclinical success sets stage for human trials and stock market interest
Hoth Therapeutics reports tumor suppression with no toxicity for HT-KIT. Learn how this biotech play could reshape cancer care and investor sentiment.